Avadel Pharmaceuticals plc
NASDAQ: AVDL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Gregory J. Divis Jr.
- Employees
- 188
- Headquarters
- Dublin, Ireland
- IPO year
- 1996
- Market cap
- $2.1B
- Website
- https://www.avadel.com
Loading AVDL…
Loading profile data…Frequently asked questions about AVDL
What does Avadel Pharmaceuticals plc (AVDL) do?
Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakne...
Where does AVDL trade?
Avadel Pharmaceuticals plc (AVDL) trades on the NASDAQ Global Market.
What sector is AVDL in?
Avadel Pharmaceuticals plc (AVDL) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Avadel Pharmaceuticals plc?
Gregory J. Divis Jr. is the chief executive officer of Avadel Pharmaceuticals plc (AVDL).
Where is Avadel Pharmaceuticals plc headquartered?
Avadel Pharmaceuticals plc is headquartered in Ireland.
Does AVDL pay a dividend?
Avadel Pharmaceuticals plc (AVDL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AVDL go public?
Avadel Pharmaceuticals plc (AVDL) completed its initial public offering in 1996.
Is AVDL an ADR?
Yes — AVDL is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Avadel Pharmaceuticals plc reporting and dividends follow the underlying issuer.